Presentations to Focus on Company’s Exosome-based and Duchenne Muscular Dystrophy
Therapies
LOS ANGELES, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Linda Marbán, Ph.D, CEO of Capricor Therapeutics, Inc. (NASDAQ: CAPR), is presenting at two conferences, the BTIG Fall
Biotechnology Conference on Thursday in New York and the American Society of Exosomes and Microvesicles Annual Meeting, which will
continue through Wednesday in Baltimore.
The American Society of Exosomes and Microvesicles meeting, which started on Saturday, brings together a diverse
array of American and international scientists with interests in the fields of exosomes, microvesicles, exRNAs and bacterial outer
membrane vesicles. Dr. Marbán provided a presentation on Sunday about the regenerative possibilities of exosome-based therapies.
Capricor is developing an exosome-based therapy, CAP-2003, as a next-generation therapeutic platform in regenerative medicine and
as a vehicle to potentially deliver therapies to cells in the human body.
At the BTIG conference on Thursday, Dr. Marbán will participate in a panel discussion of new treatments for
Duchenne muscular dystrophy, a genetic disease for which there are limited treatment options. Capricor is currently testing the
safety and efficacy of its novel cell therapy, CAP-1002, in boys and young men in advanced stages of Duchenne muscular dystrophy.
The HOPE-2 clinical trial is a Phase II, randomized, double-blind, placebo-controlled trial planning
to enroll approximately 84 subjects at up to 15 clinical trial sites.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company developing biological
therapies for Duchenne muscular dystrophy and other rare diseases. Capricor's lead candidate, CAP-1002, is a cell-based candidate
currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also exploring the potential of
CAP-2003, a cell-free, extracellular vesicle-based candidate, to treat a variety of disorders. For more information, visit
www.capricor.com.
About CAP-1002
CAP-1002 consists of allogeneic cardiosphere-derived cells, or CDCs, a unique population of cells that contains
cardiac progenitor cells. CAP-1002 has been shown to exert potent immunomodulatory activity and alters the immune system's activity
to encourage cellular regeneration. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been
administered to approximately 140 human subjects across several clinical trials.
About CAP-2003
CAP-2003 is being developed as a next-generation therapeutic platform in regenerative medicine. CAP-2003 is
comprised of nano-sized extracellular vesicles, including exosomes and microvesicles, derived from human CDCs, which exert
anti-inflammatory, pro-angiogenic, anti-apoptotic, and anti-fibrotic effects. CAP-2003 contains several characteristic lipids,
proteins, and RNA molecules (e.g., microRNAs). They act as messengers to regulate the functions of neighboring cells. Pre-clinical
research has shown that exogenously-administered extracellular vesicles can direct or, in some cases, re-direct cellular activity,
supporting their therapeutic potential. Their size, ease of crossing cell membranes and ability to communicate in native cellular
language make them an exciting class of potential therapeutic agents.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release regarding the efficacy, safety, and intended utilization of Capricor's
product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of
enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments
involving products, including the ability to obtain regulatory approvals or otherwise bring products to market; plans regarding
current and future collaborative activities and the ownership of commercial rights; scope, duration, validity and enforceability of
intellectual property rights; future royalty streams, expectations with respect to the expected use of proceeds from the recently
completed offerings and the anticipated effects of the offerings, and any other statements about Capricor's management team's
future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements
containing the words "believes," "plans," "could," "anticipates," "expects," "estimates," "should," "target," "will," "would" and
similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by such forward-looking statements. More information about
these and other risks that may impact Capricor's business is set forth in Capricor's Annual Report on Form 10-K for the year ended
December 31, 2017 as filed with the Securities and Exchange Commission on March 22, 2018, in its Registration Statement on Form
S-3, as filed with the Securities and Exchange Commission on September 28, 2015, together with the prospectus included therein and
prospectus supplements thereto and in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2018, as filed with the
Securities and Exchange Commission on August 13, 2018. All forward-looking statements in this press release are based on
information available to Capricor as of the date hereof, and Capricor assumes no obligation to update these forward-looking
statements.
CAP-1002 is an Investigational New Drug and is not approved for any indications. CAP-2003 has not yet been
approved for clinical investigation.
For more information, please contact: AJ Bergmann, Chief Financial Officer +1-310-358-3200 abergmann@capricor.com
